Postdoctoral Researcher, Pharmacist


Dr. Christos Liolios has a pharmacy degree from the Dep. of Pharmacy, National Kapodistrian University of Athens (NKUA), (2004), where he also did his master thesis in Pharmacy in pharmacognosy and chemistry of bioactive natural products (2005). In 2008, he received a scholarship from NCSR “Demokritos”, Athens for his PhD thesis on radiolabeled bombesin derivatives for SPECT (99mTc/188Re) & PET (64Cu) tomography for diagnosis and therapy of prostate cancer (PCa), which he successfully defended in 2013 in the Pharmacy Dep. Univ. of Patras. In 2014 he joined, as a post-doctoral researcher, the Div. of Radiopharmaceutical Chemistry in the German Cancer Research Centre (DKFZ), Heidelberg, Germany, which has played a protagonistic role on the development of PET-diagnosis and endoradiotherapy of PCa during the last 6 years. In 2019 he returned to Greece and he is currently working as a Post-doctoral researcher in ΕΣΠΑ/ΕΔΒΜ34 for the “Development of 68Ga-labeled magnetic iron nanoparticles targeting GRP (gastrin releasing peptide) and PSMA (prostate specific membrane antigen) receptors for molecular multimodality imaging with PET/MRI of PCa” with Dr. Penelope Bouziotis, and he is also affiliated in the Dep. Pharmacy NKUA in the lad of Med. Chemistry of Prof. A.Kolocouris.

Dr. Liolios has a strong background in radiochemistry, pharmacology/pharmacokinetics (in vitro/ in vivo assays) and medicinal chemistry (solid phase peptide synthesis, organic and bioconjugation chemistry). He has extensively worked on diagnostic/therapeutic molecules for PCa, in addition to molecules targeting receptors expressed on other types of cancer. His main scientific interest currently focuses on the development of theranostic molecules: 1) multi-targeting ligands for prostate specific membrane antigen/ gastrin releasing peptide receptors, which can be labeled either with diagnostic 68Ga or therapeutic radionuclides 177Lu, or 2) ligands combining targeted release of a toxophore in tumor cells and PET diagnosis of cancer foci.

Selected Grants

COST Action CA19114: Network for Optimized Astatine labeled Radiopharmaceuticals

2020-2024 | European Cooperation in Science and Technology (COST)

The purpose of the COST Action CA19114 entitled "Network for Optimized Astatine-labeled Radiopharmaceuticals" (NOAR) is to create a network of scientists to investigate the production conditions of the α-particle emitter Astatine-211 (Astatine-211: 211At) and its application in Targeted A...


COST Action CA17140 entitled "Nano2Clinic: Cancer Nanomedicine - from the bench to the bedside"

2018-2022 | European Cooperation in Science and Technology (COST)

The COST Action CA17140 entitled "Nano2Clinic: Cancer Nanomedicine - from the bench to the bedside" focuses on the development of nanosystems transporting anti-cancer drugs. The pan-European network of specialists from universities, research centers, clinical research organizations and companies is ...


Dual-targeting iron oxide nanoparticles against bombesin receptors (BNRs) and Prostate Specific Membrane Antigen (PSMA), radiolabeled with Gallium-68, as PET/MRI imaging agents for prostate cancer

2020-2021 | ΕΣΠΑ/Εκπαίδευση και Δια Βίου Μάθηση

The present research project is focused on the development of iron oxide nanoparticles (IONPs) radiolabeled with 68Ga, for dual-modality molecular imaging of prostate cancer with PET/MRI. These NPs are functionalized with adequate pharmacophores (peptides or peptidomimetic molecules) so a...

INRASTES - Official Web Site
Skip to content